First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
Clinical trial NCT03869632 · UNKNOWN
Trial details
- NCT number
- NCT03869632
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-19
- Primary completion
- 2021-04-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.